New irradiation facility for biomedical applications at the RA-3 reactor thermal column.

A new irradiation facility has been developed in the RA-3 reactor in order to perform trials for the treatment of liver metastases using boron neutron capture therapy (BNCT). RA-3 is a production research reactor that works continuously five days a week. It had a thermal column with a small cross section access tunnel that was not accessible during operation. The objective of the work was to perform the necessary modifications to obtain a facility for irradiating a portion of the human liver. This irradiation facility must be operated without disrupting the normal reactor schedule and requires a highly thermalized neutron spectrum, a thermal flux of around 10(10) n cm(-2)s(-1) that is as isotropic and uniform as possible, as well as on-line instrumentation. The main modifications consist of enlarging the access tunnel inside the thermal column to the suitable dimensions, reducing the gamma dose rate at the irradiation position, and constructing properly shielded entrance gates enabled by logical control to safely irradiate and withdraw samples with the reactor at full power. Activation foils and a neutron shielded graphite ionization chamber were used for a preliminary in-air characterization of the irradiation site. The constructed facility is very practical and easy to use. Operational authorization was obtained from radioprotection personnel after confirming radiation levels did not significantly increase after the modification. A highly thermalized and homogenous irradiation field was obtained. Measurements in the empty cavity showed a thermal flux near 10(10) n cm(-2)s(-1), a cadmium ratio of 4100 for gold foils and a gamma dose rate of approximately 5 Gy h(-1).

Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: application to the treatment of experimental oral cancer.

The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1 x 10(9) n cm(-2)s(-1) and the fast neutron flux was 2.5 x 10(6) n cm(-2)s(-1), indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in (6)Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.